Overview

Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients. Patients will be monitored for recurrence as well as safety, and immune responses related to the injections.

Phase:

Phase 2

Details

Lead Sponsor:

GlobeImmune

Treatments:

Gemcitabine
Pancreatin
Pancrelipase